<DOC>
	<DOCNO>NCT02852967</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , efficacy KD025 adult subject moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>This Study Being Conducted Evaluate Safety , Tolerability , Efficacy KD025 Administered Orally 16 Weeks Subjects With Moderate Severe Plaque Psoriasis Who Are Candidates Systemic Therapy Phototherapy .</brief_title>
	<detailed_description>This study perform adult male female subject moderate severe chronic plaque psoriasis candidate systemic therapy phototherapy . Study drug orally administer double-blind fashion 16 week order evaluate efficacy 16 week treatment . Approximately 150 subject randomly assign 1 5 dose cohort : - 200 mg KD025 daily ( QD ) - 200 mg KD025 BID - 400 mg KD025 QD - 600 mg/day KD025 ( administer 400 mg morning 200 mg evening ) - Placebo BID</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Adult subject age 18 65 year Able provide write ICF prior performance study specific procedure Has diagnosis moderate severe chronic plaque psoriasis candidate systemic therapy phototherapy Has PASI ≥ 12 within 24hour period prior first dose study drug Has least 10 % body surface area affect plaque psoriasis within 24hour period prior first dose study drug Willing avoid tan device Have adequate bone marrow function : Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Hemoglobin &gt; 9.0 g/dL Platelets &gt; 100,000/mm3 Have adequate safety laboratory value : Serum total bilirubin within normal limit ( WNL ) AST ALT &lt; 2 × upper limit normal ( ULN ) Serum creatinine &lt; 1.5 × ULN Female subject childbearing potential negative pregnancy test screening . Females childbearing potential define sexually mature woman without prior hysterectomy evidence menses past 12 month . However , woman amenorrheic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , antiestrogens , ovarian suppression Women childbearing potential ( i.e. , menstruate woman ) must negative urine pregnancy test ( positive urine test confirm serum test ) document within 24hour period prior first dose study drug Sexually active woman childbearing potential enrol study must agree use two form accept method contraception course study 3 month last dose study drug . Effective birth control include ( ) IUD plus one barrier method ; ( b ) stable dos hormonal contraception least 3 month ( e.g. , oral , injectable , implant , transdermal ) plus one barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) ; ( ) vasectomize partner For male patient sexually active partner premenopausal woman : agreement use two form contraception criterion 5 treatment period least 3 month last dose study drug Willing complete study measurement assessment compliance protocol Has nonplaque druginduced ( antimalarial , lithium ) psoriasis ( If subject take angiotensin II receptor blocker beta blocker dos must stable 6 month prior study entry ) Use highdose corticosteroid ( &gt; 10 mg prednisone equivalent ) within 12 week prior study , immunosuppressive therapy within 4 week prior study entry Use methotrexate , retinoids ( acitretin ) , calcineurin inhibitor ( cyclosporine ) within 4 week prior study entry Using phototherapy within 4 week prior study entry Using biologic therapy , include antibody IL17 , antiTNFα , antiIL12 &amp; 23 , within 3 month prior study entry Has active viral , fungal , bacterial skin infection ( nail fungal infection ) . Is pregnant lactate woman Has history GI surgery include bariatric surgery , gastrointestinal condition might interfere drug absorption Currently participate another study investigational drug within 28 day 5 halflives investigational drug ( whichever longer ) study entry Has history evidence severe illness condition would make subject , opinion investigator , unsuitable study Regular and/or excessive use alcohol within 2 year prior study entry define alcohol intake &gt; 14 drink per week man &gt; 7 drink per week woman . Approximately 10 g alcohol equal one `` drink '' unit . One unit equal 1 ounce distil spirit , one 12ounce beer , one 4ounce glass wine Has QTc ( F ) interval ( QT interval data correct use Fridericia 's formula ) &gt; 450 msec ( average 3 reading ) screening Has exposure KD025 know allergy/sensitivity KD025 within last 6 month prior study entry ROCK2 inhibitor History presence following : ALT AST &gt; 2.0 × ULN screening . ( Subjects isolate AST elevation magnitude , ratio AST : ALT &gt; 1.5 interviewed regard use alcohol , level repeat participation study discuss medical monitor . ) Renal disease and/or serum creatinine &gt; 1.5 × ULN screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Skin Diseases</keyword>
	<keyword>Auto-Immune Diseases</keyword>
	<keyword>Plaque</keyword>
	<keyword>Dermatology</keyword>
</DOC>